In a landmark moment for Indian biotechnology, Dr. Jitendra Singh, Union Minister of Science and Technology, announced the soft launch of India’s first indigenous antibiotic, Nafithromycin. Developed with the support of the Biotechnology Industry Research Assistance Council (BIRAC) and marketed under the trade name Miqnaf by Wockhardt, this breakthrough aims to combat drug-resistant Community-Acquired Bacterial Pneumonia (CABP), a global health threat causing over two million deaths annually.
What Sets Nafithromycin Apart?

• 10x Efficacy: Clinical trials have demonstrated that Nafithromycin is ten times more effective than existing antibiotics like azithromycin.

• Short Treatment Duration: Just a three-day regimen is sufficient, a significant improvement over conventional treatments.

• Wide Pathogen Coverage: Targets both typical and atypical bacteria, ensuring comprehensive treatment.

• Safety & Tolerability: Minimal gastrointestinal side effects, no significant drug interactions, and unaffected by food intake.

• First in Decades: This is the first new antibiotic in its class globally in over 30 years.

Why It Matters
India accounts for 23% of the global pneumonia burden, with a rising challenge of antimicrobial resistance (AMR). Existing treatments have shown declining efficacy due to widespread misuse and resistance, particularly in vulnerable groups like children, the elderly, and immunocompromised patients.
“Nafithromycin represents a game-changer in addressing the AMR crisis, paving the way for safer and faster recovery for millions of patients,” said Dr. Jitendra Singh.
Innovation Backed by Collaboration
The development of Nafithromycin highlights the power of public-private collaboration, with 14 years of dedicated research and ₹500 crore in investments. Clinical trials conducted across the U.S., Europe, and India have validated its efficacy and safety. The drug now awaits final approval from the Central Drugs Standard Control Organization (CDSCO) for manufacturing and public use.
Industry Perspectives
Dr. Balbir Singh, Chairman, Cardiology at Max Superspeciality Hospital, praised the innovation as a much-needed addition to India’s fight against drug resistance. Dr. Vanita Arora, Clinical Lead at Apollo Hospitals Delhi, highlighted the antibiotic’s retrievability and advanced features as critical advancements in patient care.
The Road Ahead
Dr. Jitendra Singh emphasized that antimicrobial resistance is one of the most pressing health threats globally, requiring sustained investments and collaborative efforts. He called on stakeholders from the government, pharmaceutical industry, and research institutions to strengthen India’s role as a global leader in biotechnology.
“This breakthrough underscores India’s potential to develop homegrown solutions to address critical healthcare challenges, placing the country at the forefront of innovation in combating AMR,” he said.
Key Takeaways for Pharmacists & Healthcare Providers

• Be Prepared: Nafithromycin offers a revolutionary treatment for CABP and should be stocked to meet anticipated demand.

• Educate Patients: Highlight the benefits of this shorter, more effective treatment regimen.

• Stay Informed: AMR awareness is critical—ensure compliance with prescription practices to mitigate resistance development.